Despite many pleas for ceramide-based treatment regimens against cancer (Radin, 2003), progression from cell-culture to in vivo applications has been slow, and no clinical trials have been reported to date.
During progression from normal cell to tumor cell and consequent metastasis, the cells are exposed to a range of apoptotic stresses.
Most cancers are epithelial in origin and arise through a stepwise progression from normal cells, through dysplasic cells, into malignant cells [ 34].
The progression from normal cell, subject to stringent growth controls, to an unregulated tumor cell is a stepwise process of accumulating mutations and rearrangements in the genome [ 1], which may disrupt, inhibit or deregulate genes, or create novel fusion genes.
For animals and plants, the progression from single cell to adult clearly includes an embryo.
Ultimately, this experimental approach would be expected to support investigations on the malignant progression from CIS cell to TGCT.
However, the percentage and intensity of high Bmi-1 expression were significantly increased following the progression from columnar cell metaplasia to adenocarcinoma.
The progression from plasma cell to MMC is characterized by multiple oncogenic events, such as hyperdiploidy and deregulation of cyclin D1.
The pathogenesis of ESCC is thought to include a stepwise progression from basal cell hyperplasia (BCH) to low-grade dysplasia (LGD), high-grade dysplasia (HGD), carcinoma in situ, and finally invasive carcinoma.
In our previous studies, the percentage and intensity of BMI1 expression significantly increased during the progression from columnar cell metaplasia to Barrett esophagus, low- and high-grade dysplasia, and adenocarcinoma [ 25].
